Investors - The IPIX Opportunity, do you believe in the Science and shrug off emotional chatter - Big Pharma does. The opportunity window to "stock up" under $1.00/share will close and shortly thereafter it will take off suddenly due to a high level of interest and opportunity from Big Pharma and others Biotechs.
Here's the opportunity:
Invest in IPIX and your supporting and believing in not 1 but 3 Novel Molecules with First in Class Mechanisms of Actions in High Unmet Need populations where patients are suffering and physicians are looking for better answers. I personally own six figures shares. The first in class opportunity in high dollar markets is reminding me of another opportunity I believed in - a BTK inhibitor that was bought out for $261 a share only a few years ago. IPIX is WAY under valued too.
Example: High Unmet Need and Big Market Potential for Prurisol: Theres a commerical running non-stop for a psoriasis biologic medication that brings in $2 Billion a year and read the label, causes many to have depression and suicidal thoughts and many other nasty Adverse Effects and patients relapse.
IPIX OVERVIEW from the IPIX website
Innovation has developed three lead drug candidates—each with first-in-class potential across multiple clinical indications attributable to novel mechanisms of action—with dermatology, oncology, anti-inflammatory and antibiotic applications.
Prurisol—an orally-delivered medicine for treating psoriasis
Kevetrin—a non-genotoxic cancer drug that modulates p53
Brilacidin—an immunomodulatory agent with anti-inflammatory/antibiotic properties
Based on sound science, and covered by strong intellectual property and patent protections, these drug candidates are in mid-to-late stage clinical trials.
Advancing under a number of special FDA designations to help expedite development, improve likelihood of drug approval and gain market exclusivity, they address large areas of unmet medical need and represent sizable commercial opportunities.
